Kronos Bio To Present Preliminary Data From Phase 1 Dose Escalation Portion Of Ongoing Phase 1/2 KB-0742 Study At The Connective Tissue Oncology Society Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Kronos Bio will present preliminary data from the Phase 1 dose escalation portion of the ongoing Phase 1/2 KB-0742 study at the Connective Tissue Oncology Society Annual Meeting. The data will be shared by Brian Van Tine, M.D., of Washington University School of Medicine.
October 27, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Kronos Bio's presentation of preliminary data from the ongoing Phase 1/2 KB-0742 study could potentially impact the company's stock.
The presentation of preliminary data from an ongoing study is a significant event for a biotech company like Kronos Bio. Depending on the results, it could either boost investor confidence if the data is positive, or cause concern if the data is not as expected. However, as the data is preliminary, the impact is uncertain at this point.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100